Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans

Oncology Reviews

Volumn 5, Issue 2, 2011, Pages 77-92

  Scholler, Julie ^a   Levêque, Dominique ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Cancer; Dasatinib; Drug transporters; Enzymes; Erlotinib; Gefitinib; Imatinib; Kinase inhibitor; Lapatinib; Nilotinib; Pazopanib; Pharmacokinetics; Sorafenib; Sunitinib

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CAPECITABINE; CARBAMAZEPINE; CYTOCHROME P450; DASATINIB; ERLOTINIB; GEFITINIB; GEMCITABINE; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; IMATINIB; IRINOTECAN; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; METHOTREXATE; METOPROLOL; MULTIDRUG RESISTANCE PROTEIN; NILOTINIB; ORGANIC CATION TRANSPORTER; ORPHAN NUCLEAR RECEPTOR; PAZOPANIB; PHENYTOIN; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; SIMVASTATIN; SORAFENIB; SUNITINIB; VORICONAZOLE;

AREA UNDER THE CURVE; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; GRAPEFRUIT JUICE; HUMAN; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

EID: 79960443209     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-011-0072-5     Document Type: Review

References (103)

1. A Levitzki A Gazit 1995 Tyrosine kinase inhibition: an approach to drug development Science 267 1782 1788 7892601 1:CAS:528:DyaK2MXkslWgtL4%3D
2. DS Krause RA van Etten 2005 Tyrosine kinases as targets for cancer therapy New Engl J Med 353 172 187 16014887 1:CAS:528:DC%2BD2MXmtFClsbs%3D (Pubitemid 41058349)
3. JT Hartmann M Haap HG Kopp, et al. 2009 Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects Curr Drug Metab 10 470 481 19689244 1:CAS:528:DC%2BD1MXhtVGhtbzN
4. D Levêque F Maloisel 2005 Clinical pharmacokinetics of imatinib mesylate In Vivo 19 77 84 15796158 (Pubitemid 40450380)
5. LJ Christopher D Cui C Wu, et al. 2008 Metabolism and disposition of dasatinib after oral administration to humans Drug Metab Dispos 36 1357 1364 18420784 1:CAS:528:DC%2BD1cXotVensr4%3D (Pubitemid 351929320)
6. C Tanaka OQP Yin V Sethuraman, et al. 2010 Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib Clin Pharmacol Ther 87 197 203 19924121 1:CAS:528:DC%2BC3cXhtFaltbY%3D
7. HC Swaisland RP Smith A Laight, et al. 2005 Single-dose clinical pharmacokinetics studies of gefitinib Clin Pharmacokinet 44 1165 1177 16231967 1:CAS:528:DC%2BD2MXhtlSgtbrJ (Pubitemid 41483701)
8. P Frohna J Lu S Eppler, et al. 2006 Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects J Clin Pharmacol 46 282 290 16490804 1:CAS:528: DC%2BD28Xitl2qsbs%3D (Pubitemid 43260315)
9. JF Lu SM Eppler J Wolf, et al. 2006 Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer Clin Pharmacol Ther 80 136 145 16890575 1:CAS:528:DC%2BD28XotFKhtr8%3D (Pubitemid 44160689)
10. QSC Chu G Schwartz J de Bono, et al. 2007 Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies J Clin Oncol 25 3753 3758 17704424 1:CAS:528: DC%2BD2sXhtVeqt7fF (Pubitemid 47372617)
11. KM Koch NJ Reddy RB Cohen, et al. 2009 Effects of food on the relative bioavailability of lapatinib in cancer patients J Clin Oncol 27 1191 1196 19188677 1:CAS:528:DC%2BD1MXktFKhsL8%3D
12. A Awada A Hendlisz T Gil, et al. 2005 Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours Br J Cancer 92 1855 1861 15870716 1:CAS:528:DC%2BD2MXkt1Sgsrw%3D (Pubitemid 40826133)
13. D Strumberg H Richly RA Hilger, et al. 2005 Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors J Clin Oncol 23 965 972 15613696 1:CAS:528:DC%2BD2MXit1Ggu7c%3D (Pubitemid 46202316)
14. R Khosravan M Toh M Garrett, et al. 2010 Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function J Clin Pharmacol 50 472 481 19779038 1:CAS:528:DC%2BC3cXks1CltL4%3D
15. EI Heath EG Chiorean CJ Sweeney, et al. 2010 A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors Clin Pharmacol Ther 88 818 823 20980999 1:CAS:528:DC%2BC3cXhsVegu7bE
16. D McKillop M Hutchinson EA Pardridge, et al. 2004 Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man Xenobiotica 34 917 934 15764411 1:CAS:528:DC%2BD2cXhtFGmu77I (Pubitemid 39648170)
17. J Ling KA Johnson Z Miao, et al. 2006 Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers Drug Metab Dispos 34 420 426 16381666 1:CAS:528:DC%2BD28Xit1Sgt74%3D (Pubitemid 43290900)
18. NP van Erp H Gelderblom MO Karlsson, et al. 2007 Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib Clin Cancer Res 13 7394 7400 18094422
19. N Nebot S Crettol F d'Esposito, et al. 2010 Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes Br J Pharmacol 161 1059 1069 20977456 1:CAS:528:DC%2BC3cXhtl2ms7jL
20. L Wang LJ Christopher D Cui, et al. 2008 Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics Drug Metab Dispos 36 1828 1839 18556438 1:CAS:528:DC%2BD1cXhtVymu7bL
21. AV Kamath J Wang FY Lee, et al. 2008 Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL Cancer Chemother Pharmacol 61 365 376 17429625 1:CAS:528:DC%2BD1cXisl2ksr4%3D (Pubitemid 350275972)
22. D McKillop AD McCormick A Millar, et al. 2005 Cytochrome P450-dependent metabolism of gefitinib Xenobiotica 35 39 50 15788367 1:CAS:528: DC%2BD2MXisVyis7k%3D (Pubitemid 40459216)
23. J Li M Zhao P He, et al. 2007 Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes Clin Cancer Res 13 3731 3737 17575239 1:CAS:528:DC%2BD2sXmsFCqu7k%3D (Pubitemid 46955138)
24. X Li TM Kamenecka MD Cameron 2009 Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities Chem Res Toxicol 22 1736 1742 19803472 1:CAS:528:DC%2BD1MXht1WntrbJ
25. A Rakhit MP Pantze S Fettner, et al. 2008 The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimmCYP™) predicts in vivo metabolic inhibition Eur J Clin Pharmacol 64 31 41 18000659 1:CAS:528:DC%2BD1cXjsFyhuw%3D%3D
26. B Peng P Llyod H Schran 2005 Clinical pharmacokinetics of imatinib Clin Pharmacokinet 44 879 894 16122278 1:CAS:528:DC%2BD2MXhtFSktbzF (Pubitemid 41252840)
27. X Li Y He CH Ruiz, et al. 2009 Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways Drug Metab Dispos 37 1242 1250 19282395 1:CAS:528:DC%2BD1MXmslamu7s%3D
28. HC Swaisland M Ranson RP Smith, et al. 2006 Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol Clin Pharmacokinet 44 1067 1081
29. X Li TM Kamenecka MD Cameron 2010 Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile Drug Metab Dispos 38 1238 1245 20382753 1:CAS:528: DC%2BC3cXos1Kltr8%3D
30. Y Liu J Ramirez L House, et al. 2010 Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases Drug Metab Dispos 38 32 39 19850672
31. WC Teng JW Oh LS New, et al. 2010 Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib Mol Pharmacol 78 693 703 20624855 1:CAS:528:DC%2BC3cXht1eisLrI
32. A Hamada H Miyano H Watanabe, et al. 2003 Interaction of imatinib mesylate with human P-glycoprotein J Pharmacol Exp Ther 307 824 828 12975485 1:CAS:528:DC%2BD3sXos1Shsbw%3D (Pubitemid 37310701)
33. J Thomas L Wang RE Clark, et al. 2004 Active transport of imatinib into and out of cells: implications for drug resistance Blood 104 3739 3745 15315971 1:CAS:528:DC%2BD2cXhtVGltb3M (Pubitemid 39564452)
34. H Dai P Marbach M Lemaire, et al. 2003 Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux J Pharmacol Exp Ther 304 1085 1092 12604685 1:CAS:528:DC%2BD3sXit1eisrs%3D (Pubitemid 36254421)
35. PJ Houghton GS Germain FC Harwood, et al. 2004 Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN38 in vitro Cancer Res 64 2333 2337 15059881 1:CAS:528:DC%2BD2cXis1yjt7s%3D (Pubitemid 38523883)
36. C Hirayama H Watanabe R Nakashima, et al. 2008 Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells Pharm Res 25 827 835 17934801 1:CAS:528:DC%2BD1cXkt1SnsbY%3D (Pubitemid 351661829)
37. S Hu RM Franke KK Filipski, et al. 2008 Interaction of imatinib with human organic ion carriers Clin Cancer Res 14 3141 3148 18483382 1:CAS:528:DC%2BD1cXmtVCmuro%3D
38. H Burger H van Tol AWM Boersma, et al. 2004 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump Blood 104 2940 2942 15251980 1:CAS:528:DC%2BD2cXpslKju7s%3D (Pubitemid 39434984)
39. L Wang A Giannoudis S Lane, et al. 2008 Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia Clin Pharmacol Ther 83 258 264 17568400 1:CAS:528:DC%2BD1cXitFKjtb4%3D
40. DL White P Dang J Engler, et al. 2010 Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukaemia treated by imatinib J Clin Oncol 28 2761 2767 20421539 1:CAS:528:DC%2BC3cXoslyktbc%3D
41. Y Chen S Agarwal NM Shaik, et al. 2009 P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib J Pharmacol Exp Ther 330 956 963 19491323 1:CAS:528:DC%2BD1MXhtVyitL3F
42. A Giannoudis A Davies CM Lucas, et al. 2008 Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia Blood 112 3348 3354 18669873 1:CAS:528:DC%2BD1cXht1Omur3O
43. DK Hiwase V Saunders D Hewett, et al. 2008 Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications Clin Cancer Res 14 3881 3888 18559609 1:CAS:528:DC%2BD1cXntlWrtL4%3D
44. C Hegedus C Özvegy-Laczka A Apati, et al. 2009 Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties Br J Pharmacol 158 1153 1164 19785662 1:CAS:528:DC%2BD1MXhsVSks7fM
45. DL White VA Saunders P Dang, et al. 2006 OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib Blood 108 697 704 16597591 1:CAS:528:DC%2BD28XntFehur0%3D (Pubitemid 44061372)
46. A Davies NE Jordanides A Giannoudis, et al. 2009 Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major transporters Leukemia 23 1999 2006 19710702 1:CAS:528:DC%2BD1MXhtl2hsrvO
47. M Dohse C Scharenberg S Shukla, et al. 2010 Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib and dasatinib Drug Metab Dispos 38 1371 1380 20423956 1:CAS:528:DC%2BC3cXhtVWktrnN
48. CF Stewart M Leggas JD Schuetz, et al. 2004 Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice Cancer Res 64 7491 7499 15492275 1:CAS:528:DC%2BD2cXosFynurg%3D (Pubitemid 39372093)
49. Y Nakamura M Oka H Soda, et al. 2005 Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance Cancer Res 65 1541 1546 15735043 1:CAS:528:DC%2BD2MXhsFKqtb8%3D (Pubitemid 40270183)
50. J Li G Cusatis J Brahmer, et al. 2007 Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients Cancer Cell Biol 6 432 438 1:CAS:528: DC%2BD2sXhtVeqsbvF (Pubitemid 47328313)
51. A Azzariti L Porcelli GM Simone, et al. 2010 Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences Cancer Chemother Pharmacol 65 335 346 19495754 1:CAS:528:DC%2BD1MXhsVKnsL7M
52. -/- (triple-knockout) and wild-type mice Mol Cancer Ther 7 2280 2287 18723475 1:CAS:528:DC%2BD1cXhtVWksL7N
53. JW Polli JE Humphreys KA Harmon, et al. 2008 The role of efflux and uptake transporters in N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2- (methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, Lapatinib) disposition and drug interactions Drug Metab Dispos 36 695 701 18216274 1:CAS:528:DC%2BD1cXktVeltb0%3D (Pubitemid 351468376)
54. S Hu Z Chen R Franke, et al. 2009 Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters Clin Cancer Res 15 6062 6069 19773380 1:CAS:528:DC%2BD1MXhtF2lur7J
55. MJ Gnoth S Sandmann K Engel M Radtke 2010 In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate towards P-glycoprotein Drug Metab Dispos 38 1341 1346 20413726 1:CAS:528:DC%2BC3cXhtVWktrjL
56. T Hegedus L Örfi A Seprödi, et al. 2002 Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1 Biochim Biophys Acta 1587 318 325 12084474 1:CAS:528:DC%2BD38XkslKju7g%3D (Pubitemid 34655800)
57. T Shen YH Kuang CR Ashby Jr., et al. 2009 Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10) PLoS One 4 e7520 19841739
58. ®) reverses multidrug resistance by inhibiting the activity of the ABCB1/P-gp and ABCG2/BCRP/MXR transporters Biochem Pharmacol 78 153 161 19427995 1:CAS:528:DC%2BD1MXmsVCjt7c%3D
59. C Brendel C Scharenberg M Dohse, et al. 2009 Imatinib mesylate and nilotinib (AMN107) exhibit high affinity interaction with ABCG2 on primitive hematopoietic stem cells Leukemia 21 1267 1275 (Pubitemid 46831816)
60. C Özvegy-Laczka T Hegedus G Varady, et al. 2004 High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter Mol Pharmacol 65 1485 1495 15155841 (Pubitemid 38668306)
61. M Leggas JC Panetta Y Zhuang, et al. 2006 Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo Cancer Res 66 4802 4807 16651435 1:CAS:528:DC%2BD28XjvF2kt78%3D
62. N Takigawara M Takeyama T Kozuki, et al. 2007 Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells Oncol Rep 17 983 987
63. K Yanase S Tsukahara S Asada, et al. 2004 Gefitinib reverses breast cancer resistance protein-mediated drug resistance Mol Cancer Ther 3 1119 1125 15367706 1:CAS:528:DC%2BD2cXnsFajtL8%3D (Pubitemid 39295009)
64. Z Shi XX Peng IW Kim, et al. 2007 Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance Cancer Res 67 11012 11020 18006847 1:CAS:528:DC%2BD2sXhtlSlsLrF (Pubitemid 350145931)
65. K Noguchi H Kawahara A Kaji, et al. 2009 Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib Cancer Sci 100 1701 1707 19493273 1:CAS:528:DC%2BD1MXhtFOhurnM
66. CL Dai AK Tiwari CP Wu, et al. 2008 Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2 Cancer Res 68 7905 7914 18829547 1:CAS:528:DC%2BD1cXhtF2msL3P
67. YH Kuang T Shen X Chen, et al. 2010 Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance Biochem Pharmacol 79 154 161 19720054 1:CAS:528:DC%2BD1MXhsVWqtbbM
68. S Agarwal R Sane JR. Ohlfest, et al. 2011 The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib in the brain J Pharmacol Exp Ther 336 223 233 20952483 1:CAS:528:DC%2BC3MXls1eqtg%3D%3D
69. H Kawahara K Noguchi K Katayama, et al. 2010 Pharmacological interaction with sunitinib is abolished by a germ-line mutation (1291T>C) of BCRP/ABCG2 gene Cancer Sci 101 1493 1500 20345483 1:CAS:528:DC%2BC3cXns1SksLk%3D
70. S Shukla RW Robey SE Bates, et al. 2009 Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2 Drug Metab Dispos 37 359 365 18971320 1:CAS:528:DC%2BD1MXhs1Krsbo%3D
71. CL Dai YJ Liang YS Wang, et al. 2009 Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2 Cancer Lett 279 74 83 19232821 1:CAS:528:DC%2BD1MXltlejt7w%3D
72. S Harmsen I Meijerman JH Beijnen JHM Schellens 2009 Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor Cancer Chemother Pharmacol 64 35 43 18839173 1:CAS:528:DC%2BD1MXlt1Kjsbw%3D
73. ER Gardner H Burger RH van Schaik, et al. 2006 Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib Clin Pharmacol Ther 80 192 201 16890580 1:CAS:528:DC%2BD28XotFKht70%3D (Pubitemid 44160695)
74. H Gurney M Wong RL Balleine, et al. 2007 Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype Clin Pharmacol Ther 82 33 40 17495881 1:CAS:528:DC%2BD2sXotVGju78%3D (Pubitemid 46944197)
75. S Dulucq S Bouchet B Turcq, et al. 2008 Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukaemia Blood 112 2024 2027 18524988 1:CAS:528:DC%2BD1cXhtVyksr7M
76. A Pétain D Kattygnarath J Azard, et al. 2008 Population pharmacokinetics and pharmacogenetics of imatinib in children and adults Clin Cancer Res 14 7102 7109 18981009
77. DH Kim L Sriharsha W Xu, et al. 2009 Clinical relevance of a pharmacogenetic approach using multiple candidates genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia Clin Cancer Res 15 4750 4758 19584153 1:CAS:528:DC%2BD1MXosV2ltbg%3D
78. HC Swaisland MV Cantarini R Fuhr A Holt 2006 Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics Clin Pharmacokinet 45 633 644 16719544 1:CAS:528:DC%2BD28XmvVCmtrg%3D (Pubitemid 44046489)
79. AE Bolton B Peng M Hubert, et al. 2004 Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects Cancer Chemother Pharmacol 53 102 106 14605865 1:CAS:528:DC%2BD3sXhtVSjsLfJ (Pubitemid 38186987)
80. RF Frye SM Fitzgerald TF Lagattuta, et al. 2004 Effect of St John's wort on imatinib mesylate pharmacokinetics Clin Pharmacol Ther 76 323 329 15470331 1:CAS:528:DC%2BD2cXotlCmtLg%3D (Pubitemid 39313122)
81. C Tanaka OQP Yin T Smith, et al. 2011 Effect of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants J Clin Pharmacol 51 75 83 20702754 1:CAS:528:DC%2BC3MXovV2hug%3D%3D
82. M Hamilton JL Wolf J Rusk, et al. 2006 Effects of smoking on the pharmacokinetics of erlotinib Clin Cancer Res 12 2166 2171 16609030 1:CAS:528:DC%2BD28XjtlChs7w%3D
83. DA Smith KM Koch N Arya, et al. 2009 Effects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects Br J Clin Pharmacol 67 421 426 19371315 1:CAS:528:DC%2BD1MXlvFSjurY%3D
84. C Dutreix B Peng G Mehring, et al. 2004 Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects Cancer Chemother Pharmacol 53 290 294 (Pubitemid 39304422)
85. E Gambillara E Laffite N Widmer, et al. 2005 Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia Dermatology 211 363 365 16286749 1:STN:280:DC%2BD2Mngs1CmtA%3D%3D (Pubitemid 41642114)
86. MJ Egorin DD Shah SM Christner, et al. 2009 Effect of a proton pump inhibitor on the pharmacokinetics of imatinib Br J Clin Pharmacol 68 370 374 19740393 1:CAS:528:DC%2BD1MXht1ylsLzI
87. FM Johnson S Agrawal H Burris, et al. 2010 Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors Cancer 116 1582 1591 20108303 1:CAS:528:DC%2BC3cXktFGgsLc%3D
88. OQP Yin N Gallagher D Fischer, et al. 2010 Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib J Clin Pharmacol 50 960 967 20498287 1:CAS:528:DC%2BC3cXhtVCmsL3J
89. OQP Yin N Gallagher A Li, et al. 2010 Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants J Clin Pharmacol 50 188 194 19948946 1:CAS:528:DC%2BC3cXks1Sksbg%3D
90. C Lathia J Lettieri F Cihon, et al. 2006 Lack of effect of ketoconazole-mediated CYP3A4 inhibition on sorafenib clinical pharmacokinetics Cancer Chemother Pharmacol 57 685 692 16133532 1:CAS:528:DC%2BD28Xjs1KktLk%3D
91. SG O'Brien P Meinhardt E Bond, et al. 2003 Effect of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia Br J Cancer 89 1855 1859 14612892 (Pubitemid 37533259)
92. M Veeraputhiran M Sundermeyer 2008 Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin Clin Lung Cancer 9 232 234 18650173 1:CAS:528:DC%2BD1cXhtVWntb%2FF
93. Y Wang L Zhou C Dutreix, et al. 2008 Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukemia Br J Clin Pharmacol 65 885 892 18384443 1:CAS:528:DC%2BD1cXnvFCgsrc%3D (Pubitemid 351677440)
94. T Grenader M Gipps L Shavit, et al. 2007 Significant drug interaction: phenytoin toxicity due to erlotinib Lung Cancer 57 404 406 17383767 (Pubitemid 47285413)
95. S Onoda H Mitsufuji N Yanase, et al. 2005 Drug interaction between gefitinib and warfarin Jpn J Clin Oncol 35 478 482 16006576 (Pubitemid 41309202)
96. BC Goh NJ Reddy UB Dandamudi, et al. 2010 An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5 + 1 cocktail in patients with advanced solid tumors Clin Pharmacol Ther 88 652 659 20881954 1:CAS:528:DC%2BC3cXhtlWmurjL
97. T Dragovich M Huberman DD Von Hoff, et al. 2007 Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial Cancer Chemother Pharmacol 60 295 303 17149608 1:CAS:528:DC%2BD2sXltFSktbg%3D (Pubitemid 46742546)
98. RM van Hest JB Schnog MB van't Veer, et al. 2008 Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated by imatinib Am J Hematol 83 757 758 18615671
99. WL Furman F Navid NC Daw, et al. 2009 Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors J Clin Oncol 27 4599 4604 19687340 1:CAS:528:DC%2BD1MXhtlCns7%2FJ
100. WA Messersmith DA Laheru NN Senzer, et al. 2004 Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): early termination due to increased toxicities Clin Cancer Res 10 6522 6527 15475439 1:CAS:528:DC%2BD2cXot1Oiur8%3D (Pubitemid 39346546)
101. K Mross S Steinbild F Baas, et al. 2007 Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib Eur J Cancer 43 55 63 17095207 1:CAS:528:DC%2BD2sXmtVemtA%3D%3D (Pubitemid 46054474)
102. EB Haura T Tanvetyanon A Chiappori, et al. 2010 Phase I/II of the src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer J Clin Oncol 28 1387 1394 20142592 1:CAS:528:DC%2BC3cXksFSqur0%3D
103. G Demetri PG Casali JY Blay, et al. 2009 A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors Clin Cancer Res 15 5910 5916 19723647 1:CAS:528:DC%2BD1MXhtFars7rK